Seema Naik is an Oncology physician affiliated with Pennsylvania State University. OpenAlex indexes 153 publications with 1,320 citations (h-index 19); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
500 University Dr
Hershey, PA 170332360
Telephone
717-531-8401Registry record last updated 8 May 2017.
Clinical trials
- Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Sponsor: Milton S. Hershey Medical Center
- Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML
Sponsor: Milton S. Hershey Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
- Janssen Biotech, Inc.Program year20252 payments
- Novartis Pharmaceuticals CorporationProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
19.3%Kinase inhibitor8.4%Brukinsa29%Calquence21%Jaypirca20%Jakafi12%Imbruvica10%Iclusig9%Part D<11 patientsThalidomide Analog7.3%Lenalidomide40%Pomalyst38%Revlimid22%Part D<11 patients+ 2 more classes in this area
Anti-infectives
17.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor6.2%Valacyclovir100%Part D≥32 patientsMacrolide Antimicrobial3.7%Azithromycin100%Part D≥30 patients+ 6 more classes in this area
Nervous system
16.1%Opioid Agonist8.1%Oxycodone Hcl62%Morphine Sulfate Er11%Oxycodone-Acetaminophen10%Tramadol Hcl9%Fentanyl8%Part D<11 patientsGabapentinoids4%Gabapentin74%Pregabalin26%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Ramin Zand, MD, MPH
Pennsylvania State University
Allan Lipton, MD
Pennsylvania State University
Steven Ettinger, MD
Pennsylvania State University
Gerald Naccarelli, MD
Pennsylvania State University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”